-
33181.生物医学工程中心研究年报，第2卷
[医药制造业] [2013-12-21]
The Center for Biomedical Engineering Research, CBER, is an interdisciplinary center whose mission is to provide engineering science and clinical technology to reduce the impact of disease on the everyday life of individuals. It was created to provide an appropriate forum and infrastructure to promote the interaction of biomedical researchers from the university and the medical community. As such, CBER serves as a research umbrella under which investigators from a variety of fields can work together.
关键词：生物医药；医学研究；临床医学
-
33182.HEB焦平面成像技术的安全性和生物医学应用
[医药制造业] [2013-12-21]
We have demonstrated a low-noise heterodyne three-element focal plane array (FPA) at 1.6 THz consisting of NbN Hot Electron Bolometric (HEB) detectors, intimately integrated with monolithic microwave integrated circuit (MMIC) IF amplifiers in a single block. HEB technology is becoming the basis for advanced terahertz imaging and spectroscopic technologies for the study of biological and chemical agents over the entire terahertz spectrum. The use of FPAs is crucial for maximizing the detection speed in these applications.
关键词：生物医药；焦平面成像技术；生物医学应用
-
33183.化学/辐射激效数据库，评估Hormetic机制及其生物医学和风险评估的启示
[医药制造业] [2013-12-21]
This project assessed the biomedical and toxicological literature for evidence of hormesis, its frequency in the literature and its underlying mechanistic foundation. This work was supported by the continued development of the hormesis database and the conduct of a high level international conference on hormesis held annually. Particular focus was given to the area of neuroscience and hormesis in the literature assessment. Fourteen manuscripts concerning hormesis and neuroscience have been accepted for publication in the journal Critical Reviews in Toxicology and will be published in 2008.
关键词：生物医药；辐射；数据库
-
33184.2013年12月（上半月）医药行业要闻综述
[医药制造业] [2013-12-20]
《第一财经日报》12月2日报道，当地时间11月26日，美国纽约东区联邦地区法院做出终审裁决，判定被告中国华北制药集团（下称“华药集团”）下属河北维尔康制药有限公司（下称“维尔康”）在美国维C反垄断案中败诉，赔偿原告Ranis公司1.53亿美元（约合9.34亿元）。在此之前，同样作为被告的石家庄制药集团维生药业（下称“石药维生药业”）、江苏江山制药及东北制药三家公司已经选择和解，向原告支付了约3400万美元的和解赔偿金。至此，长达8年的维生素C国际诉讼案，终审以4家中国被告公司3家庭外和解、1家公司败诉收场。
关键词：医药行业；要闻综述
-
33185.2013年11月化学药品原药产量
[医药制造业,化学原料和化学制品制造业] [2013-12-20]
关键词：11月；化学药品；原药产量
-
33186.2013年11月中成药产量
[医药制造业] [2013-12-20]
关键词：11月；中成药产量
-
33187.2013年11月中西药品零售额
[医药制造业] [2013-12-20]
关键词：11月；中西药品；零售额
-
33188.失控的乙肝疫苗：康泰生物致2死1伤白云山或步重啤后尘
[医药制造业] [2013-12-20]
关键词：乙肝疫苗；康泰生物
-
33189.在哺乳动物DNA甲基化研究中的统计算法
[医药制造业,信息传输、软件和信息技术服务业] [2013-12-18]
DNA methylation is a dynamic chemical modification that is abundant on DNA sequences and plays a central role in the regulatory mechanisms of cells. This modification can be inherited across cell divisions and generations, providing a “memory mechanism” for regulatory programs that is more flexible than that coded in the DNA sequence. In recent years, high-throughput sequencing technologies have enabled genome-wide annotation of DNA methylation. Coupled with novel computational machinery, these developments have enabled unperceivable insight to the characteristics,biological function and disease association of this phenomenon.
关键词：DNA甲基化；统计算法
-
33190.去除雄激素和放疗对于前列腺癌治疗的免疫反应调制
[医药制造业] [2013-12-17]
Although the combination of radiation therapy and androgen deprivation therapy (ADT) is initially effective in many patients, biochemical failure rates of 20at 5-years to 50at 10-years have been reported, highlighting the need for improved treatments, particularly for men with high- risk prostate cancer. ADT in the neo-adjuvant setting is used to reduce tumor volume and improve the response to radiation. Additionally, ADT causes infiltration of lymphocytes into the prostate. B cell infiltrates may promote prostate cancer progression and development of castration resistant prostate cancer by the production of inflammatory cytokines and skewing CD4+ T cell responses towards Th2. We hypothesized that depletion of B cells at the time of castration would improve tumor control. Our results demonstrate that the depletion of B cells at the time of castration improves tumor latency.
关键词：医药；治疗技术；前列腺癌；免疫反应
027-87841330